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CPAP = continuous positive airways pressure; FEV1 = forced expired volume in 1 sec; FRC = functional residual capacity; FVC = forced vital
capacity; MEF75, MEF50, and MEF25 = maximal expiratory flows at the 75%, 50%, and 25% of vital capacity; MEF25-75 = maximal expiratory flow
between 25% and 75% of the FVC; PaCO2 = arterial carbon dioxide; PaO2 = arterial oxygen; PEEPI = intrinsic positive end-expiratory pressure;
PEF = peak expiratory flow; Pplat = end-inspiratory plateau pressure; Q = perfusion; V = ventilation; VE = minute ventilation; VEI = end-inspired
volume above apneic FRC.
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Bronchial asthma has a wide clinical spectrum ranging from a
mild, intermittent disease to one that is severe, persistent, and
difficult to treat, which in some instances can also be fatal
[1–4]. Asthma deaths, although uncommon (one in 2000
asthmatics), have increased over the last decades [2], with
more than 5000 deaths reported annually in the USA and
100,000 deaths estimated yearly throughout the world [1,2].
Patients at greater risk for fatal asthma attacks are mainly
those with severe, unstable disease, although death can
occur to anyone if the asthma attack is intense enough [2–4].
Most deaths from asthma are preventable, however, particu-
larly those among young persons. Morbidity in asthma is a
considerable problem, and is mainly related to the more
severe phenotypes of the disease. The nature of severe,
chronic asthma and its optimal management measures
remain poorly understood. Patients affected have also the
greatest impact on healthcare costs, which have increased
rapidly over the last years.
Severity in asthma is difficult to define and its characterization
should take into account four components: biological severity
(yet to be elucidated in asthma); physiological severity (where
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Abstract
Severe asthma, although difficult to define, includes all cases of difficult/therapy-resistant disease of all
age groups and bears the largest part of morbidity and mortality from asthma. Acute, severe asthma,
status asthmaticus, is the more or less rapid but severe asthmatic exacerbation that may not respond
to the usual medical treatment. The narrowing of airways causes ventilation perfusion imbalance, lung
hyperinflation, and increased work of breathing that may lead to ventilatory muscle fatigue and life-
threatening respiratory failure.
Treatment for acute, severe asthma includes the administration of oxygen, β2-agonists (by continuous or
repetitive nebulisation), and systemic corticosteroids. Subcutaneous administration of epinephrine or
terbutaline should be considered in patients not responding adequately to continuous nebulisation, in
those unable to cooperate, and in intubated patients not responding to inhaled therapy. The exact time
to intubate a patient in status asthmaticus is based mainly on clinical judgment, but intubation should not
be delayed once it is deemed necessary. Mechanical ventilation in status asthmaticus supports gas-
exchange and unloads ventilatory muscles until aggressive medical treatment improves the functional
status of the patient. Patients intubated and mechanically ventilated should be appropriately sedated,
but paralytic agents should be avoided. Permissive hypercapnia, increase in expiratory time, and
promotion of patient-ventilator synchronism are the mainstay in mechanical ventilation of status
asthmaticus. Close monitoring of the patient’s condition is necessary to obviate complications and to
identify the appropriate time for weaning. Finally, after successful treatment and prior to discharge, a
careful strategy for prevention of subsequent asthma attacks is imperative.
Keywords difficult/therapy-resistant asthma, dynamic hyperinflation, fatal asthma, permissive hypercapnia, status
asthmaticusAvailable online http://ccforum.com/content/6/1/030
the key measures for its definition are pulmonary function
tests and assessment of symptom scores); functional severity
(that represents the impact of the disease on an individual’s
ability to perform age-appropriate activities); and burden of
illness (viewed in terms of the emotional, social, and financial
impact of asthma on the individual, the family and society as a
whole) [5].
A large number of terms are used by clinicians when referring
to asthmatic patients who have severe disease that is difficult
to treat. The National Institute of Health Guidelines for the
Diagnosis and Management of Asthma have characterized
severe, persistent asthma, in untreated patients, by the pres-
ence of several criteria: continual symptoms (also occurring
frequently at night) that cause limitations in physical activity;
frequent exacerbations; persistent airflow obstruction with
forced expired volume in 1 sec (FEV1) and/or peak expiratory
flow (PEF) of less than 60% of the predicted value; and PEF
diurnal variability greater than 30% [1].
Severe asthma, defined as disease that is unresponsive to
current treatment, including systemically administered corti-
costeroids, is an important subset of asthma and it is esti-
mated that 5–10% of all patients are affected [6]. ‘Difficult
asthma’, defined as the asthmatic phenotype characterized
by failure to achieve control despite maximally recommended
doses of inhaled steroids prescribed, encompasses a great
proportion of patients with severe, persistent asthma [7]. The
term ‘brittle asthma’ describes subgroups of patients with
severe, unstable asthma who maintain a wide PEF variability
despite high doses of inhaled steroids [8]. The classification
of this relatively rare phenotype of asthma into two types has
been recently suggested. Type 1 brittle asthma is character-
ized by a wide, persistent and chaotic PEF variability (>40%
diurnal variation for >50% of the time over a period of at least
150 days) despite considerable medical therapy. Type 2
brittle asthma is characterized by sudden acute attacks
occurring in less than three hours, without an obvious trigger,
on a background of apparent normal airway function or well-
controlled asthma [8].
Nocturnal asthma (‘early morning dip’) is the commonest
pattern of instability in asthma and usually denotes subopti-
mal treatment. Some unstable patients with asthma may
present an early morning and an additional evening deteriora-
tion pattern in lung function (‘double dip’). Premenstrual
asthma is a characteristic pattern of instability in asthma
where an increase in symptoms and a decrease in PEF are
observed two to five days before the menstrual period, with
improvement once menstruation begins. Premenstrual exac-
erbation of asthma, although usually mild and responsive to
an increase in antiasthmatic therapy, may also be severe and
appear steroid-resistant.
Steroid-resistant asthma refers to those (rare) patients with
chronic asthma who are unresponsive to the administration of
high dose of steroids (10–14 day course of 20 mg or more,
twice daily, of prednisone) [9,10]. Steroid-dependent asthma
is defined as asthma that can be controlled only with high
doses of oral steroids and may be part of a continuum with
steroid-resistant asthma at the other extreme. Aspirin-induced
asthma, adult-onset asthma and asthma with ‘fixed’ obstruc-
tion are also patterns of severity in asthma. Recently, the
European Respiratory Society Task Force on Difficult/
Therapy-Resistant Asthma adopted such a term to include all
the above-described cases of severe, and ‘difficult to treat’
disease of all age groups [11].
Acute, severe asthma
Asthma exacerbations are acute or subacute episodes of
breathlessness, cough, wheezing, and chest tightness, or any
combination of these symptoms. Exacerbations are associ-
ated with airways obstruction that should be documented
and quantified by PEF or FEV1 measurement. Objective mea-
sures of airways obstruction in most asthmatics are consid-
ered more reliable to indicate the severity of an exacerbation
than changes in the severity of symptoms. The intensity of
asthma exacerbations may vary from mild to severe. Among
patients attending an emergency department, the severity of
obstruction in terms of FEV1 is, on average, 30–35% of pre-
dicted normal [12].
Status asthmaticus
Acute, severe asthma describes the serious asthmatic attack
that places the patient at risk of developing respiratory failure,
a condition referred to as status asthmaticus [13,14]. The time
course of the asthmatic crisis as well as the severity of airways
obstruction may vary broadly [14]. In some patients who
present with asthmatic crisis, repeated PEF measurements
when available may document subacute worsening of expira-
tory flow over several days before the appearance of severe
symptoms, the so-called ‘slow onset asthma exacerbation’. In
others, however, lung function may deteriorate severely in less
than one hour, the so-called ‘sudden onset asthma exacerba-
tion’ [14,15]. Slow onset asthma exacerbations are mainly
related to faults in management (inadequate treatment, low
compliance, inappropriate control, coexisting psychological
factors) that should be investigated and corrected in every
patient in advance. On the other hand, massive exposure to
common allergens, sensitivity to nonsteroidal anti-inflammatory
agents, and sensitivity to food allergens and sulphites are
mainly considered the triggers in sudden asthma exacerba-
tions. Without prompt and appropriate treatment, status asth-
maticus may result in ventilatory failure and death.
Fatal asthma
Two different patterns of fatal asthma have been described
(Table 1). The greater number of deaths from asthma
(80–85%) occurs in patients with severe and poorly con-
trolled disease who gradually deteriorate over days or weeks,
the so-called ‘slow onset – late arrival’ or type 1 scenario of
asthma death [2–4,16–18]. This pattern of asthma death isCritical Care    February 2002 Vol 6 No 1 Papiris et al.
generally considered preventable. A variation of this pattern is
a history of unstable disease, which is partially responsive to
treatment, upon which a major attack is superimposed. In both
situations, hypercapnic respiratory failure and mixed acidosis
ensues and the patient succumbs to asphyxia, or if mechanical
ventilation is applied, to complications such as barotrauma
and ventilator-associated pneumonia. Pathologic examination
in such cases shows extensive airways plugging by dense and
tenacious mucous mixed to inflammatory and epithelial cells,
epithelial denudation, mucosal edema, and an intense
eosinophilic infiltration of the submucosa. In a small proportion
of patients, death from asthma can be sudden and unex-
pected (sudden asphyxic asthma), without obvious
antecedent long-term deterioration of asthma control, the so-
called ‘sudden onset’ or type 2, scenario of asthma death
[18–21]. Affected individuals develop rapidly severe hyper-
capnic respiratory failure with combined metabolic and respi-
ratory acidosis, and succumb to asphyxia. If treated (medically
and/or mechanically ventilated), however, they present a faster
rate of improvement than patients with slow-onset asthmatic
crisis. Pathologic examination in such cases shows ‘empty’
airways (no mucous plugs) in some patients, and in almost all
patients, a greater proportion of neutrophils than eosinophils
infiltrating the submucosa is observed [20–22].
Risk factors
Patients at high risk of asthma death require special attention
and, in particular, intensive education, monitoring and care.
Risk factors for death from asthma are [1]:
1. Past history of sudden severe exacerbations.
2. Prior intubation for asthma.
3. Prior admission for asthma to an intensive care unit.
4. Two or more hospitalizations for asthma in the past year.
5. Three or more emergency care visits for asthma in the
past year.
6. Hospitalization or an emergency care visit for asthma
within the past month.
7. Use of >2 canisters per month of inhaled short-acting
β2-agonist.
8. Current use of systemic corticosteroids or recent with-
drawal from systemic corticosteroids.
9. Difficulty perceiving airflow obstruction or its severity.
10. Comorbidity, as from cardiovascular diseases or chronic
obstructive pulmonary disease.
11. Serious psychiatric disease or psychosocial problems.
12. Low socioeconomic status and urban residence.
13. Illicit drug use
14. Sensitivity to alternaria.
Pathophysiology
Asthma is an inflammatory disease of the airways that
appears to involve a broad range of cellular- and cytokine-
mediated mechanisms of tissue injury [1]. In asthmatic sub-
jects who die suddenly of an asthma attack, the peripheral
airways frequently exhibit occlusion of the bronchial lumen by
inspissated secretions, thickened smooth muscles, and
bronchial wall inflammatory infiltration and edema [22,23].
These changes observed in the asthmatic airways support
the hypothesis that peripheral airways occlusion forms the
pathologic basis of the gas exchange abnormalities observed
in acute, severe asthma. In such patients, widespread occlu-
sion of the airways leads to the development of extensive
areas of alveolar units in which ventilation (V) is severely
reduced but perfusion (Q) is maintained (i.e. areas with very
low V/Q ratios, frequently lower than 0.1) [24].
Hypoxemia, hypercapnia and lactic acidosis
Intrapulmonary shunt appears to be practically absent in the
majority of patients because of the collateral ventilation, the
effectiveness of the hypoxic pulmonary vasoconstriction,
and the fact that the airway obstruction can never be func-
tionally complete [24]. Hypoxemia is therefore common in
every asthmatic crisis of some severity; mild hypoxia is
easily corrected with the administration of relatively low
concentrations of supplemental oxygen [25]. More severe
hypoxemia and the need for higher concentrations of sup-
plemental oxygen may relate to some contribution of shunt
physiology.
Table 1
Different patterns of fatal asthma
Scenario of asthma death
Variable Type 1 Type 2
Time course Subacute worsening (days). ‘Slow onset – late arrival’ Acute deterioration (hours). ‘Sudden asphyxic asthma’
Frequency ≅ 80–85% ≅ 15–20%
Airways Extensive mucous plugging  More or less ‘empty’ bronchi 
Inflammation Eosinophils Neutrophils
Response to treatment Slow Faster
Prevention Possible (?)Analysis of arterial blood gases is important in the manage-
ment of patients with acute, severe asthma, but it is not pre-
dictive of outcome. In the early stages of acute, severe
asthma, analysis of arterial blood gases usually reveals mild
hypoxemia, hypocapnia and respiratory alkalosis. If the deteri-
oration in the patient’s clinical status lasts for a few days
there may be some compensatory renal bicarbonate secre-
tion, which manifests as a non-anion-gap metabolic acidosis.
As the severity of airflow obstruction increases, arterial
carbon dioxide (PaCO2) first normalizes and subsequently
increases because of patient’s exhaustion, inadequate alveo-
lar ventilation and/or an increase in physiologic death space.
Hypercapnia is not usually observed for FEV1 values higher
than 25% of predicted normal, but in general, there is no cor-
relation between airflow rates and gas exchange markers.
Furthermore, paradoxical deterioration of gas exchange, while
flow rates improve after the administration of β-adrenergic
agonists is not uncommon.
Respiratory acidosis is always present in hypercapnic
patients who rapidly deteriorate and in severe, advanced-
stage disease, metabolic (lactic) acidosis may coexist. The
pathogenesis of lactic acidosis in the acutely severe asth-
matic patient remains to be fully elucidated. There are several
mechanisms that are probably involved [13]: the use of high-
dose parenteral β-adrenergic agonists; the highly increased
work of breathing resulting in anaerobic metabolism of the
ventilatory muscles and overproduction of lactic acid; the
eventually coexisting profound tissue hypoxia; the presence
of intracellular alkalosis; and the decreased lactate clearance
by the liver because of hypoperfusion.
During an asthma attack, all indices of expiratory flow, includ-
ing FEV1, FEV1/FVC (forced vital capacity), PEF, maximal
expiratory flows at 75%, 50%, and 25% of vital capacity
(MEF75, MEF50, and MEF25 respectively) and maximal expira-
tory flow between 25% and 75% of the FVC (MEF25–75) are
reduced significantly. The abnormally high airway resistance
observed (5–15 times normal) is directly related to the short-
ening of airway smooth muscle, edema, inflammation, and
excessive luminal secretions, and leads to a dramatic
increase in flow-related resistive work of breathing. Although
the increased resistive work significantly contributes to
patient functional status, however, the elastic work also
increases significantly, and enhances respiratory muscle
fatigue and ventilatory failure [26,27].
Dynamic hyperinflation
In asthmatic crisis, remarkably high volumes of functional
residual capacity (FRC), total lung capacity and residual
volume can be observed, and tidal breathing occurs near pre-
dicted total lung capacity. Lung hyperinflation that develops
as a result of acute airflow obstruction, however, can also be
beneficial since it improves gas exchange. The increase in
lung volume tends to increase airway caliber and conse-
quently reduce the resistive work of breathing. This is accom-
plished, however, at the expense of increased mechanical
load and elastic work of breathing.
Lung hyperinflation in acute, severe asthma, is primarily
related to the fact that the highly increased airway expiratory
resistance, the high ventilatory demands, the short expiratory
time, and the increased post-inspiratory activity of the inspira-
tory muscles (all present at variable degrees in patients in
status asthmaticus) do not permit the respiratory system to
reach static equilibrium volume at the end of expiration
(Fig. 1). Inspiration, therefore, begins at a volume in which the
respiratory system exhibits a positive recoil pressure. This
pressure is called intrinsic positive-end expiratory pressure
(PEEPI) or auto-PEEP. This phenomenon is called dynamic
hyperinflation and is directly proportional to minute ventilation
(VE) and to the degree of airflow obstruction.
Dynamic hyperinflation has significant unfavorable effects on
lung mechanics. First, dynamic hyperinflation shifts tidal
breathing to a less compliant part of the respiratory system
pressure–volume curve leading to an increased pressure–
volume work of breathing. Second, it flattens the diaphragm
and reduces generation of force since muscle contraction
results from a mechanically disadvantageous fiber length.
Third, dynamic hyperinflation increases dead space, thus
increasing the minute volume required to maintain adequate
ventilation. Conceivably, asthma increases all three compo-
nents of respiratory system load, namely resistance, elas-
tance, and minute volume. Finally, in acute severe asthma, the
diaphragmatic blood flow may also be reduced. Under these
overwhelming conditions, in the case of persistence of the
severe asthma attack, ventilatory muscles cannot sustain ade-
quate tidal volumes and respiratory failure ensues.
Effects of asthma on the cardiovascular system
Acute, severe asthma alters profoundly the cardiovascular
status and function [28,29]. In expiration, because of the
effects of dynamic hyperinflation, the systemic venous return
decreases significantly, and again rapidly increases in the
next respiratory phase. Rapid right ventricular filling in inspira-
tion, by shifting the interventricular septum toward the left
ventricle, may lead to left ventricular diastolic dysfunction and
incomplete filling. The large negative intrathoracic pressure
generated during inspiration increases left ventricular after-
load by impairing systolic emptying. Pulmonary artery pres-
sure may also be increased due to lung hyperinflation,
thereby resulting in increased right ventricular afterload.
These events in acute, severe asthma may accentuate the
normal inspiratory reduction in left ventricular stroke volume
and systolic pressure, leading to the appearance of pulsus
paradoxus (significant reduction of the arterial systolic pres-
sure in inspiration). A variation greater than 12 mmHg in sys-
tolic blood pressure between inspiration and expiration
represents a sign of severity in asthmatic crisis. In advanced
stages, when ventilatory muscle fatigue ensues, pulsus para-
Available online http://ccforum.com/content/6/1/030doxus will decrease or disappear as force generation
declines. Such status harbingers impeding respiratory arrest.
Clinical and laboratory assessment
Patients with acute, severe asthma appear seriously dyspneic
at rest, are unable to talk with sentences or phrases, are agi-
tated and sit upright (Table 2) [1]. Drowsiness or confusion
are always ominous signs and denote imminent respiratory
arrest. Vital signs in acute, severe asthma are: respiratory rate
usually >30 breaths/min; heart rate >120 beats/min; wheez-
ing throughout both the inspiration and the expiration; use of
accessory respiratory muscles; evidence of suprasternal
retractions; and pulsus paradoxus >12 mmHg.
Pulsus paradoxus can be a valuable sign of asthma severity
but its detection should not delay prompt treatment. Paradoxi-
cal thoracoabdominal movement and the absence of pulsus
paradoxus suggest ventilatory muscle fatigue and, together
with the disappearance of wheeze and the transition from
tachycardia to bradicardia, represent signs of imminent respi-
ratory arrest. The usual cardiac rhythm in acute, severe
asthma is sinus tachycardia, although supraventricular
arrhythmias are not uncommon. Less frequently ventricular
arrhythmias may be observed in elderly patients.
Electrocardiographic signs of right heart strain such as right
axis deviation, clockwise rotation, and evidence of right ven-
tricular hypertrophy may be observed in acute, severe asthma
and usually resolve within hours of effective treatment [30].
Physical examination should be especially directed toward
the detection of complications of asthma: pneumothorax;
pneumomediastinum; subcutaneous emphysema; pneu-
mopericardium; pulmonary interstitial emphysema; pneu-
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Figure 1
Relationship of volume and pressure in the respiratory system.
Dynamic hyperinflation adds an elastic load to inspiratory muscles: to
initiate inspiratory flow the inspiratory muscles must first overcome
intrinsic positive end-expiratory pressure (PEEPI). Dynamic
hyperinflation shifts tidal breathing to a less compliant part of the
respiratory system pressure–volume curve leading to an increased








Clinical and functional assessment of severe asthma exacerbations
Variable Severe exacerbation Imminent respiratory arrest
Symptoms
Dyspnea At rest
Speech  Single words, not sentences of phrases
Alertness Agitated  Drowsy or confused
Signs
Respiratory rate  >30 breaths/min
Heart rate >120 beats/min Bradycardia
Pulsus paradoxus >25 mmHg Absence (muscle fatigue)
Use of accessory muscles Evident Abdominal paradox 
Wheeze Present – loud ‘Silent chest’
Functional assessment




PaCO2, arterial carbon dioxide; PaO2, arterial oxygen; PEF, peak expiratory flow; SaO2, oxygen saturation. Adapted from the National Heart, Lung
and Blood Institute report [1].moretroperitoneum; tracheoesophageal fistula (in the
mechanically ventilated); cardiac arrhythmias, myocardial
ischemia or infarction; mucous plugging, atelectasis; pneu-
monia; sinusitis; coexisting vocal cord dysfunction; theo-
phylline toxicity; electrolyte disturbances (hypokalemia,
hypophosphatemia, hypomagnesemia); lactic acidosis; and
hyperglycemia.
Complications of acute, severe asthma
Pneumothorax eventually associated with pneumomedi-
astinum, subcutaneous emphysema (Fig. 2), pneumoperi-
cardium and tracheoesofageal fistula (in the mechanically
ventilated patient) (Fig. 3) are rare but potentially severe
complications of acute, severe asthma. Myocardial ischemia
should be considered in older patients with coronary artery
disease. Mucus plugging and atelectasis are not rare and
usually respond to effective treatment. Other complications
to consider include theophylline toxicity, lactic acidosis,
electrolyte disturbances (hypokalemia, hypophosphatemia,
hypomagnesemia), myopathy and ultimately anoxemic brain
injury [13].
Patient monitoring
Close monitoring by serial measurements of lung function
(PEF or FEV1 at bedside) to quantify the severity of airflow
obstruction and its response to treatment are of paramount
importance. PEF or FEV1 <30–50% of predicted or personal
best indicates severe attack. Attention should be paid to
measuring lung function in the severely ill patient, however,
because the deep inspiration maneuver involved in PEF or
FEV1 measurement may precipitate respiratory arrest by
worsening bronchospasm [31]. Failure of treatment to
improve expiratory flow predicts a more severe course and
the need for hospitalization [32].
Blood gas analysis
Although arterial blood gas analysis is useful in the manage-
ment of patients with acute, severe asthma, it is not predictive
of outcome. Arterial blood gas determinations are necessary
in the more severe asthmatic crisis, when oxygen saturation is
lower than 90%, and in the case of no response or deteriora-
tion. In such cases, analysis of blood gases usually reveals
severe hypoxemia with arterial oxygen (PaO2) lower than
60 mmHg, hypocapnia and respiratory alkalosis with or
without compensatory metabolic acidosis. As the severity of
airflow obstruction increases, PaCO2 first normalizes and
subsequently increases. The transition from hypocapnia to
normocapnia is an important sign of severe clinical deteriora-
tion and the appearance of hypercapnia probably indicates
the need for mechanical ventilation [13]. Hypercapnia per se
is not an indication for intubation, however, and such patients
may respond successfully to the application of aggressive
medical therapy [1].
Metabolic acidosis denotes impeding respiratory arrest.
Repeated measurements of blood gases may be necessary in
severe patents to determine clinical deterioration or improve-
ment, and may offer additional information to clinical judg-
ment and PEF measurements.
Chest radiography
Chest radiographs in the majority of patients with acute
asthma will be normal [33] but chest radiographic examina-
tion is a valuable tool to exclude complications. The cost of
the radiographic examination is relatively inexpensive, and
the radiation risk is low, therefore, since severe asthmatic
attacks may be associated with some complication, it would
seem that a chest radiogram would be indicated in all asth-
matic attacks of sufficient severity to bring the patient in the
emergency department. Chest radiographic examination,
however, should never be permitted to delay initiation of
treatment.
Blood counts, drug-monitoring, and electrolytes
Complete blood counts may be appropriate in patients with
fever and/or purulent sputum. Determination of serum theo-
phylline levels is mandatory in every patient under treatment
with theophylline. Finally, it would be prudent to measure
electrolytes in patients who have been taking diuretics regu-
larly and in patients with cardiovascular disease because
excessive use of β2-agonists may decrease serum levels of
potassium, magnesium, and phosphate.
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Figure 2
Pneumomediastinum-bilateral pneumothorax in an intubated patient in
status asthmaticus. Radiolucent stripes along the soft tissues of the
mediastinum, and the continuous diaphragm sign indicate the presence
of pneumomediastinum. Bilateral pneumothorax is also seen (deep
costophrenic sulcuses and hyperlucent hemidiaphragms bilaterally).
Subcutaneous emphysema is also seen on the left of the figure.Hospitalization
The immediate prognosis of acute asthma is usually not
determined by the intensity of the presenting symptoms or by
the severity of the airways obstruction in terms of PEF or
FEV1, but rather by the acute response to treatment [32,34].
In general, and for those patients who are not immediate can-
didates for admission to the intensive care unit, four to six
hours of treatment in the emergency department have been
considered necessary before deciding on disposition
[13,35]. Further studies, however, have shown that the great
majority of patients (77%) resolve their symptoms within two
hours of presentation, and there is little to be gained by pro-
longing treatment in the emergency department [34].
There are a number of additional factors that may influence
the decision to hospitalize a patient [1]: duration and severity
of symptoms; severity of airflow obstruction; course and
severity of prior exacerbations; medication use at the time of
exacerbation, (access to medical care and medications); ade-
quacy of support and home conditions; and presence of psy-
chiatric illness. Admission to an intensive care unit is
mandatory in patients in respiratory arrest, altered mental
status and serious concomitant cardiac complications. This
should be guaranteed in every patient with severe airflow
obstruction who demonstrates a poor response to treatment,
or in any patient who deteriorates despite therapy [13]. For
less severe patients who continue to have an incomplete
response (PEF or FEV1 <60% predicted) after two hours of
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Figure 3
Tracheoesophageal fistula in an intubated patient in status asthmaticus (iatrogenic complication). (a) The chest x-ray shows an abnormal distension
of the fundus of the stomach. (b) The overinflated balloon of the endotracheal tube is evident in the computerized tomography of the chest and
upper abdomen. The lumen of the endotracheal tube is seen centrally. The nasogastric tube is slightly displaced on the left by the endotracheal
balloon and indicates the position of the esophagus. (c) At lower level, the trachea has a normal configuration. The nasogastric tube is again seen,
but the esophagus is dilated with air (tracheoesophageal fistula). (d) Extensive dilatation of the fundus of the stomach is seen. The nasogastric
junction is indicated by the visualization of the nasogastric tube.continuous nebulization with β2-agonists in the emergency
department, admission to the general medical ward is recom-
mended.
Management
Early treatment of asthma exacerbations should be the best
strategy for management [1,36]. Furthermore, patients at high
risk of asthma-related death require special attention, particu-
larly intensive education, monitoring, and care. Patients, their
families and their physicians, however, frequently underesti-
mate the severity of asthma. Important elements for the pre-
vention of exacerbations and for early asthma treatment
include [1]:
1. A written action plan for home self-management of
asthma exacerbations, especially for those patients with
severe asthma or a history of previous severe asthma
attacks.
2. Provide the patient with the necessary skills to recognize
early signs of asthma worsening.
3. Clear instructions for appropriate intensification of
therapy in case of deterioration.
4. Prompt communication between patient and clinician
about any serious deterioration of asthma control.
Early home management of asthma exacerbations is of para-
mount importance since it avoids treatment delay and pre-
vents clinical deterioration. The effectiveness of care
depends on the abilities of the patients and/or their families,
and on the availability of emergency care equipment (peak
flow meter, appropriate medications, nebulizer, and eventu-
ally, supplemental oxygen).
Pharmacologic management
In the emergency department, a brief history regarding time of
onset, cause of exacerbation, severity of symptoms (espe-
cially in comparison to previous attacks), prior hospitalizations
and/or emergency department visits for asthma, prior intuba-
tion or intensive care admission, and complicating illness may
be useful for treatment decisions. The primary therapies for
acute severe asthma include, the administration of oxygen,
inhaled β2-agonists, and systemic corticosteroids. The inten-
sity of pharmacological treatment and patient’s surveillance
should correspond to the severity of the exacerbation [1].
Oxygen treatment (by nasal cannulae or mask) is recom-
mended for most patients who present with severe exacerba-
tion in order to maintain oxygen saturation >90% (>95% in
pregnant women and in patients with coexistent cardiac
disease).
Inhaled β β2-agonists
Continuous or repetitive nebulisation of short-acting β2-ago-
nists is the most effective means of reversing airflow obstruc-
tion and can be given safely. Continuous nebulisation of
β2-agonists may be more effective in children and severely
obstructed adults [37–39]. Salbutamol (albuterol) is the most
frequently used agent because of its potency, duration of
action (four to six hours) and β2-selectivity. Continuous or
repetitive nebulisation of salbutamol should be preferred
because duration of activity and effectiveness of β2-agonists
are inversely related to the severity of airways obstruction
[13]. The usual dose is 2.5 mg of salbutamol (0.5 ml) in
2.5 ml normal saline for each nebulisation (Table 3) [34].
Nebulised β2-agonists should continue until a significant clini-
cal response is achieved or serious side effects appear
(severe tachycardia, or arrhythmias). Prior ineffective use of
β2-agonists does not preclude their use and does not limit
their efficacy [13]. Inhaled therapy with β2-agonists appears
to be equal to, or even better than, their intravenous infusion
in treating airways obstruction in patients with severe asthma
[13].
Anticholinergics and methylxanthines
Anticholinergics, such as ipratropium bromide (Table 3), may
be considered in the emergency treatment of asthma but
there is controversy on their ability to offer additional bron-
chodilation [40,41]. Methylxanthines, such as theophylline
(Table 3), in the emergency department are of debated effi-
cacy and not generally recommended [1,42]. Several authors,
however, consider that there is enough data demonstrating
that theophylline treatment in the emergency department ben-
efits patients after 24 hours. Its non bronchodilating proper-
ties, including its action on the diaphragm and its
anti-inflammatory effects, may thus warrant the use of theo-
phylline in the emergency care of acute, severe asthma [43].
Corticosteroid treatment
Systemic corticosteroids (to speed the resolution and reduce
relapse) are recommended for most patients in the emer-
gency department, especially those with moderate-to-severe
exacerbation and patients who do not respond completely to
initial  β2-agonist therapy [1,44,45]. The intensification of a
patient’s corticosteroids therapy, however, should begin
much earlier, at the first sign of loss of asthma control. Corti-
costeroids in the emergency department may also help to
reduce mortality from asthma [3]. Since benefits from corti-
costeroid treatment are not usually seen before six to twelve
hours, early administration is necessary. A recent study
reports for the first time that large doses of inhaled corticos-
teroids (18 mg flunisolide in three hours) administered in the
emergency department, in addition to β2-agonists, speed the
resolution of acute bronchoconstriction [46]. Furthermore,
another study recently demonstrated that a single dose of
inhaled budesonide (2.4 mg) significantly reduced sputum
eosinophils and airway hyperessponsiveness in six hours
[47]. These studies appear to also support a role for inhaled
steroid treatment in asthma exacerbations, but additional
studies are necessary to assess steroid behavior in these
conditions [48].
Long-term treatment with inhaled corticosteroids has been
shown to reduce hospitalization rates in younger patients with
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cause mortality in elderly asthmatics [50]. The optimal dose
and dosing frequency of systemic corticosteroids in the
severe hospitalized asthmatics are not clearly established.
One common approach is the intravenous administration of
60–125 mg methylprednisolone every six hours during the
initial 24–48 hours of treatment (Table 3), followed by
60–80 mg daily in improving patients, with gradual tapering
during the next two weeks [13,51]. In addition to common and
well-known side effects of corticosteroid administration
(hyperglycemia, hypertension, hypokalemia, psychosis, sus-
ceptibility to infections), myopathy should be considered seri-
ously in the intubated and mechanically ventilated patient.
Subcutaneous epinephrine and terbutaline
Subcutaneous administration of epinephrine or terbutaline
should be considered, in patients not responding adequately
to continuous nebulised salbutamol, and in those patients
unable to cooperate (depression of mental status, apnea,
coma) [52] It should also be attempted in intubated patients
not responding to inhaled therapy. Epinephrine may also be
delivered effectively down the endotracheal tube in extreme
situations [13]. Subcutaneously, 0.3–0.4 ml (1:1000) of epi-
nephrine can be administered every 20 min for three doses
(Table 3). Terbutaline can be administered subcutaneously
(0.25 mg) or as intravenous infusion starting at
0.05–0.10 µg/kg per min (Table 3). When administered sub-
cutaneously, however, terbutaline loses its β-selectivity and
offers no advantages over epinephrine [53]. Terbutaline
administered subcutaneously should be preferred only in
pregnancy because it appears safer [13]. Subcutaneous
administration of epinephrine or terbutaline should not be
avoided or delayed since it is well tolerated even in patients
older than 40–50 years with no history of cardiovascular
disease (angina or recent myocardial infarction). Intravenous
administration of β-agonists (epinephrine, salbutamol) is also
an option in extreme situations and should be considered in
the treatment of patients who have not responded to inhaled
or subcutaneous treatment, and in whom respiratory arrest is
imminent, or in patients not adequately ventilated and
severely hyperinflated, despite optimal setting of the ventila-
tor.
Other treatments
Antibiotics are not recommended for the treatment of asthma
exacerbations and should be reserved for those with evi-
dence of infection (e.g. pneumonia, sinusitis) [1]. Aggressive
hydration is not recommended for adults or older children but
may be indicated for infants and young children [1]. Chest
physical therapy, mucolytics, and sedation are not recom-
mended [1].
Mechanical ventilation
Careful and repeat assessment of patients with severe exac-
erbations is mandatory [1]. Patients who deteriorate despite
aggressive treatment should be intubated. The exact time to
intubate is based mainly on clinical judgment, but it should
not be delayed once it is deemed necessary.
Current guidelines recommend four actions regarding intu-
bation [1]. First, patients presenting with apnea or coma
should be intubated immediately. Patients who present per-
sistent or increasing hypercapnia, exhaustion, depression
of the mental status, hemodynamic instability, and refrac-
tory hypoxemia are strong candidates for ventilatory
support. Second, consultation with or collaborative man-
agement by physicians expert in ventilator management is
appropriate because mechanical ventilation of patients with
severe refractory asthma is complicated and risky. Third,
because intubation is difficult in asthma patients, it is best
done semi-electively, before respiratory arrest. Finally, intu-
bation should be performed in a controlled setting by a
physician with extensive experience in intubation and
airway management.
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Table 3
Pharmacologic management in the emergency department
Agent Dose
Salbutamol (albuterol) 2.5 mg (0.5 ml) in 2.5 ml normal saline by nebulisation continuously, or every 15–20 min until a significant clinical 
response is achieved or serious side effects appear
Epinephrine 0.3–0.4 ml of a 1:1000 solution subcutaneously every 20 min for 3 doses 
Terbutaline Preferable to epinephrine in pregnancy
β-agonists Intravenous administration should be considered in patients who have not responded to inhaled or 
subcutaneous treatment, in whom respiratory arrest is imminent
Corticosteroids Methylprednisolone 60–125 mg (intravenous) or prednisone 40 mg (oral)
Anticholinergics Ipratropium bromide 0.5 mg by nebulisation every 1–4 hours, combined with salbutamol
Methylxanthines Theophylline 5 mg/kg (intravenous) over 30 min — loading dose in patients not already on theophylline, followed 
by 0.4 mg/kg/hour intravenous maintenance dose. Serum levels should be checked within 6 hoursOnce the decision to intubate has been made, the goal is to
take rapid and complete control of the patient’s cardiopul-
monary status. The oral route for intubation appears to offer
advantages over the nasal route. It allows a larger endotra-
cheal tube that offers less resistance and greater airway
clearance possibilities. The nasal route may be preferred in
the conscious, breathless, obese patient who may be difficult
to ventilate with a bag-valve mask [13], but this requires
tubing with a smaller diameter which may be impossible to
use in patients with nasal poliposis.
Sedation during ventilation
Effective sedation is necessary to prepare for intubation and
to allow synchronism between the patient and the ventilator
[13,29]. In addition, sedation improves patient comfort,
decreases oxygen consumption and dioxide production,
decreases the risk of barotrauma, and facilitates procedures.
There appears to be no standard sedation protocol for the
asthmatic patient (Table 4). One purposed approach is the
intravenous administration of midazolam, 1 mg initially, fol-
lowed by 1 mg every 2–3 min until the patient allows position-
ing and inspection of the airway [13].
Ketamine is an intravenous general anesthetic with sedative,
analgesic, anesthetic, and bronchodilating properties that
appears useful in the emergency intubation for asthma
[54–56]. During intubation the intravenous administration of
1–2 mg ketamine/kg at a rate of 0.5 mg/kg/min results in
10–15 min of general anesthesia without significant respira-
tory depression. Bronchodilation appears within minutes after
intravenous administration and lasts 20–30 min after cessa-
tion. Because of its sympaticomimetics effects, ketamine is
contraindicated in hypertension, cardiovascular disease, high
intracranial pressure, and preeclampsia. Additional side
effects of ketamine include lowering of the seizure threshold,
altered mood, delirium, laryngospasm, and aspiration. Further-
more, since ketamine is metabolized by the liver to norketa-
mine, which also has anesthetic properties and a half-life of
about 120 minutes, drug accumulation may occur and lead to
prolonged side effects. Paralysis with the short-acting neuro-
muscular blocker, succinylcholine, may offer some additional
advantages [57].
Propofol is an excellent sedating agent since it has a rapid
onset and a rapid resolution of its action [58]. In addition it
has bronchodilating properties and since patients can be
titrated to anesthetic-depth sedation, it may avoid the need
for paralytic agents. Propofol is administered intravenously
during the peri-intubation period at a dose of 60–80 mg/min
initial infusion, up to 2 mg/kg, followed by an infusion of
5–10 mg/kg/hour as needed, and for sedation for protracted
mechanical ventilation 1–4.5 mg/kg/hour [13]. Prolonged
propofol administration may be associated with generalized
seizures, increase carbon dioxide production, and hyper-
triglyceridemia [59,60].
Opioids (e.g. morphine sulfate) are not usually recommended
for sedation in asthmatics because of their potential to induce
hypotension through a combination of direct vasodilation, his-
tamine release, and vagally-mediated bradycardia. Opioids
also induce nausea and vomiting, decrease gut motility, and
depress ventilatory drive.
The use of neuromuscular-blocking agents (e.g. vecuronium,
atracurium, cis-atracurium, pancuronium) lessens the patient–
ventilator asynchronism (thus permitting more effective venti-
lation), lowers the risk for barotrauma, reduces oxygen con-
sumption and dioxide production, and reduces lactate
accumulation. The use of paralytics, however, presents a
number of disadvantages such as myopathy, excessive
airways secretions, histamine release (atracurium), and tachy-
cardia and hypotension (pancuronium). The concomitant use
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Table 4
Sedatives used in status asthmaticus
Agents Dose  Side effects
Peri-intubation period
Midazolam 1 mg (intravenous) slowly, every 2–3 min until the patient allows positioning  Hypotension, respiratory 
and airways inspection  depression
Ketamine  1–2 mg/kg (intravenous) at a rate of 0.5 mg/kg/min Sympaticomimetics effects, 
delirium
Propofol  60–80 mg/min initial intravenous infusion up to 2.0 mg/kg, followed by an  Respiratory depression 
infusion of 5–10 mg/kg/hour as needed
Mechanical ventilation
Midazolam 1–10 mg/hour continuous intravenous infusion
Morphine sulfate 1–5 mg/hour intravenous continuous infusion Nausea, vomiting, ileus
Ketamine 0.1–0.5 mg/min (intravenous)
Propofol 1–4.5 mg/kg/hour (intravenous)  Seizures, hyperlipidemiaof corticosteroids may increase the risk for postparalytic
myopathy [61]. Paralytic agents, when administered, may be
given intermittently by bolus or continuous intravenous infu-
sion. If a continuous infusion is used, either a nerve stimulator
should be used or the drug should be withheld every four to
six hours to avoid drug accumulation and prolonged paralysis.
Currently the use of paralytics is usually recommended only in
those patients who cannot adequately be controlled with
sedation alone.
Effects of intubation
Soon after the intubation of the severe asthmatic patient and
the application of positive pressure ventilation, systemic
hypotension commonly appears. The determinant factors of
systemic hypotension are sedation, hypovolemia, and primar-
ily lung hyperinflation. Dynamic hyperinflation, as previously
discussed, occurs when the highly increased airway expira-
tory resistance prolongs expiratory flow in such a way that the
next breath interrupts exhalation of the inspired tidal volume,
leading to end-expiratory gas trapping. The mechanisms of
intrinsic positive end-expiratory pressure (PEEPI) in acute,
severe asthma are as follows:
1. Deceleration of the expiratory flow
High resistance to airflow
Shortened expiratory time
Increased post-inspiratory activity of the inspiratory 
muscles.
2. Increased expiratory muscle activity.
3. High ventilatory demands.
Additional factors in its pathogenesis are insufficient time
during expiration to equilibrate alveolar pressure with atmos-
pheric pressure, persistent inspiratory muscle activity during
expiration, and an increased expiratory muscle activity
[62,63].
Dynamic hyperinflation is directly proportional to VE and to
the degree of airflow obstruction. In the severely obstructed
patient, dynamic hyperinflation may further increase in the
immediate post intubation period, as a result of the mechani-
cal ventilation, even after the delivering of normal or reduced
VE. High levels of dynamic hyperinflation may cause hemody-
namic compromise in a somewhat similar way to that caused
by the tension pneumothorax. The large intrathoracic pres-
sures that develop due to dynamic hyperinflation increase the
right atrial pressure, leading to a decrease in venous return to
the right heart. An additional mechanism of decrease in
venous return may be related to the positive intrathoracic
pressures throughout the respiratory cycle during mechanical
ventilation. Sedation, eventually muscle relaxation, and hypov-
olemia (due to increased water loss or decreased water
uptake) reduce the mean systemic blood pressure and cause
a further decrease in venous return to the heart. The end
result may be sudden cardiovascular collapse, with systemic
hypotension and tachycardia. Similar cardiovascular effects
also may be observed in patients with tension pneumothorax.
In such cases a trial of hypoventilation (delivering of
2–3 breaths/min of 100% oxygen for few minutes) may
become necessary to exclude this eventuality. With such
setting of the ventilator, in the absence of pneumothorax, the
mean intrathoracic pressure will fall, systemic blood pressure
will rise, pulse pressure will increase, and pulse rate will fall
[13].
Ventilation control
Controlled modes of ventilation are preferred in the immedi-
ate post intubation period for different reasons. Patients in
status asthmaticus not only have an excessive work of breath-
ing but in addition most of them are intubated and mechani-
cally ventilated when ventilatory muscles are fatigued.
Previous studies have shown that at least 24 hours are
needed for complete recovery of fatigue. It appears reason-
able, therefore, to rest the muscles for some time in the con-
trolled mode of ventilation before switching the ventilator to
the assist mode.
Two different modes of controlled setting of the ventilator are
widely used. One mode is pressure-controlled ventilation,
where the airway pressure can be maintained at a predeter-
mined level independently of any eventual changes of the
mechanical properties of the respiratory system. The other
method is volume-controlled ventilation, where the ventilator
delivers a predetermined tidal volume and the airways pres-
sure becomes the dependent variable. Pressure-controlled
ventilation seems more appropriate to maintain airway pres-
sure, especially in status asthmaticus in which airways resis-
tance varies rapidly.
Correction of the hypoxemia is one of the first priorities in
setting the ventilator [64]. In non-complicated status asth-
maticus, low V/Q ratio is the predominant mechanism and
true shunt does not contribute significantly to the hypoxemia.
Correction of the hypoxemia is therefore easily obtained by
the administration of relatively low concentrations of supple-
mental oxygen. In the majority of patients, the administration
of a fraction of inspired oxygen at the level of 30–50% is suf-
ficient to raise PaO2 above 60 mmHg. Failure of this level of
fraction of inspired oxygento increase PaO2 above 60 mmHg
indicates some kind of complication (e.g. mucoid impaction
atelectasis, pneumonia, or pneumothorax). Complete correc-
tion of the respiratory acidosis is not an urgent priority and,
since it requires normalization of the PaCO2, which may
cause significant deterioration of dynamic hyperinflation, most
authors prefer a carefully used buffered therapy for the cor-
rection of patient’s pH.
The appropriate setting of the ventilator in mechanically venti-
lated patients is of paramount importance to manage, and to
avoid further significant increase of, lung hyperinflation.
Several studies have shown that for patients in status asth-
maticus, a large part of the morbidity and mortality are related
to the mechanical ventilation itself rather to the disease
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strategies that can decrease dynamic hyperinflation:
decrease of VE; increase of expiratory time; and decrease of
resistance. Controlled hypoventilation (permissive hypercap-
nia) is the recommended ventilator strategy to reduce the
degree of lung hyperinflation and provide adequate oxygena-
tion and ventilation while minimizing systemic hypotension
and barotrauma. [1,65–67]. Hypoventilation can be obtained
by decreasing either the tidal volume or the respiratory fre-
quency, or both. Hypercapnia is generally well tolerated as
long as PaCO2 does not exceed 90 mmHg and acute varia-
tions in PaCO2 are avoided. Low values of arterial pH are well
tolerated, and slow infusions of sodium bicarbonate appear
to be safe in patients with acidosis.
In the immediate post intubation period, and as a result of the
mechanical ventilation, especially when patients are ventilated
to eucapnia, dynamic hyperinflation may further increase. In
order to avoid dangerous levels of dynamic hyperinflation, the
ventilator should be set to allow sufficient exhalation time
(increasing the expiratory time) while continuing bronchodila-
tor and corticosteroid treatment (decreasing resistance to
expiratory flows). The increase in expiratory time can be
achieved by increasing inspiratory flows at the expense of
increasing peak dynamic pressures, and by the elimination of
end-inspiratory pause. The strategy of increasing expiratory
time, although less powerful than controlled hypoventilation,
decreases dynamic hyperinflation considerably, whereas it
improves cardiovascular function and gas exchange [64].
Decreasing resistance to expiratory flows includes pharmaco-
logic treatment to overcome asthma and an effort to decrease
the external resistance related to ventilator tubing.
Several studies have shown that setting the ventilator with a
level of VE of 8–10 L/min (achieved by a tidal volume of
8–10 ml/kg and respiratory rate of 11–14 breaths/min) com-
bined with an inspiratory flow rate of 80–100 L/min, may be
appropriate to avoid dangerous levels of dynamic hyperinfla-
tion (Table 5).
There are several techniques for the estimation of the level of
dynamic hyperinflation. One way is to measure the end-
inspired volume above apneic FRC (VEI) [68]. Apneic FRC is
determined by measuring the total exhaled volume of gas
during 20–40 seconds of apnea in a paralyzed patient. VEI is
the sum of the tidal volume and the volume at end exhalation
above FRC (Fig. 4). Values of VEI above a threshold value of
20 ml/kg (1.4 L in an average adult) have been shown to
predict complications of hypotension and barotrauma [68].
The need for paralysis, however, limits the use of VEI.
In the mechanically ventilated patient other estimates of the
degree of dynamic hyperinflation are the determination of the
end-inspiratory plateau pressure (Pplat) and the measure of
PEEPI [69]. To obtain both measurements patient relaxation,
but not paralysis, is necessary. Pplat is an estimate of
average end-inspiratory alveolar pressures and is easily deter-
mined by stopping flow at end-inspiration (Fig. 5). PEEPI is
the lowest average alveolar pressure achieved during the res-
piratory cycle and is obtained by an end-expiratory hold
maneuver (Fig. 6). When evaluating these methods, The
American College of Chest Physicians consensus confer-
ence on mechanical ventilation concluded that Pplat is the
best predictor of hyperinflation in ventilated asthmatic
patients and recommended that Pplat must be kept lower
than 35 cmH2O [70].
After successful treatment and when the patient’s conditions
improve, the ventilator should be switched to assisted modes
(pressure or volume), and the process of weaning should
begin. In order to improve the patient/ventilator synchronism,
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Table 5
Initial ventilator settings in status asthmaticus
Setting Recommendation
Mode Pressure-controlled  ventilation
Respiratory rate  10–15 breaths/min
Tidal volume 6–10 ml/kg
Minute ventilation  8–10 L/min 
PEEP 0 cmH2O 
Inspiratory/Expiratory ratio ≥1:3
Inspiratory flow ≥100 L/min
FIO2 Maintain SaO2 >90%
Pplat <35 cm H2O
VEI <1.4 L
FIO2, fraction of inspired oxygen; PEEP, positive end-expiratory
pressure; Pplat, end-inspiratory plateau pressure; SaO2, oxygen
saturation; VEI, end-inspired volume above apneic functional residual
capacity.
Figure 4
Measurement of the end-inspired volume (VEI) above apneic functional
residual capacity (FRC) in order to estimate lung hyperinflation. The
total exhaled volume during a period of apnea (20–60 seconds) is
measured. VEI is the volume of gas at the end of inspiration above FRC
and is the sum of the tidal volume and the volume at end exhalation
above FRC (VEE). Published with permission from American Review of
Respiratory Disease [68].
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two issues should be taken into account, the response of
ventilator to patient effort, and the response of patient effort
to ventilator-delivered breath.
Noninvasive mechanical ventilation
The indications for initiating noninvasive ventilation in acute,
severe asthma are not clearly defined, and its use is ques-
tioned [62]. Noninvasive mechanical ventilation includes
various techniques of increasing alveolar ventilation without
an endotracheal airway. The clinical application of noninva-
sive ventilation includes the use of continuous positive
airways pressure (CPAP) alone, referred as ‘mask CPAP’,
and the use of intermittent positive pressure ventilation, with
or without CPAP, referred as ‘noninvasive (intermittent) posi-
tive pressure ventilation’ [71].
The application of noninvasive ventilation in acute respiratory
failure in patients with chronic obstructive pulmonary disease
has proved to be effective and safe [72,73]. Noninvasive ven-
tilation mainly works by improving alveolar ventilation, resting
fatigued ventilatory muscles, relieving dyspnea, and improving
gas exchange, while it avoids the risks and discomfort of an
endotracheal intubation [71]. Since the pathophysiology of
acute respiratory failure in asthma is, in many ways, similar to
that of acute respiratory failure in chronic obstructive pul-
monary disease, an effort has been made to investigate the
possible application of noninvasive ventilation in acute, severe
asthma [71,74]. From these studies it appears that the appli-
cation of noninvasive ventilation by properly trained and expe-
rienced personnel, added to the standard pharmacological
therapy, might be helpful in reducing the intubation rate in a
selected group of patients in status asthmaticus. Additional
studies are necessary, however, to support use of this tech-
nique in patients with acute, severe asthma.
Prognosis of patients in status asthmaticus
Status asthmaticus carries a significant mortality, ranging
between 1 and 10% [75,76]. Among patients in status asth-
maticus admitted to an intensive care unit, between 10 and
30% required mechanical ventilation [66,77,78]. In recent
years the mortality rate of patients in status asthmaticus
requiring mechanical ventilation has decreased significantly
[62]. This decrease may reflect earlier diagnosis, aggressive
medical treatment, and improvements in mechanical ventila-
tion [62]. Death from asthma in mechanically ventilated
patients appears to be further decreased after the application
of the ‘permissive hypercapnia technique’.
Prevention of relapse
Prevention of subsequent asthma attacks is imperative.
Patients should be discharged only after they have been pro-
vided with the necessary medications (and educated how to
Figure 5
Measurement of end-inspiratory plateau pressure, an estimate of
average end-inspiratory alveolar pressures. The peak-to-plateau
gradient is easily determined by stopping flow at end-inspiration and
can be used as a measure of the severity of inspiratory airway
resistance. The plateau pressure is a reflection of the respiratory
system pressure change resulting from the delivery of the tidal volume,
added to any level of intrinsic positive end-expiratory pressure. The
plateau pressure is a useful marker of lung hyperinflation and should
be maintained at less than 30 cmH20. The dotted line indicates a high
peak-to-plateau gradient observed in status asthmaticus. Published

























Measurement of intrinsic positive end-expiratory pressure. Intrinsic
positive end-expiratory pressure is the lowest average alveolar
pressure achieved during the respiratory cycle and is obtained by an
end-expiratory hold manoeuvre. In the non-obstructed patient, alveolar
pressure (PALV) equals pressure at the airway opening (PAO) both at
end inspiration and end expiration. In the severely obstructed patient,
PALV may increase because of air trapping, and at end expiration PALV
does not equal PAO. If an expiratory hold manoeuvre is performed, PAO
will rise, reflecting the degree of lung hyperinflation. Published with
permission from Principles of Critical Care [69].
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P = 15 cmH O AO 2use them), instructions in self-assessment (PEF, symptoms
score), a follow-up appointment, and instructions for an
action plan for managing recurrence of airflow obstruction
[1]. Furthermore, an adrenaline kit should be given to patients
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